Profil
Claude Mikkelsen formerly worked at Ecron Acunova A, as Finance Director-Nordic Region from 2011 to 2012, Pharmexa A, as Vice President-Corporate Affairs & Communications from 2005 to 2009, and Affitech A, as Senior VP-Investor Relations & Communications.
Mr. Mikkelsen received his graduate degree from the University of Aalborg.
Anciens postes connus de Claude Mikkelsen
| Sociétés | Poste | Fin |
|---|---|---|
| Ecron Acunova A/S | Director of Finance/CFO | 01/01/2012 |
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Public Communications Contact | 16/06/2009 |
Affitech A/S
 Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Public Communications Contact | - |
Formation de Claude Mikkelsen
| University of Aalborg | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Health Technology |
Affitech A/S
Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Health Technology |
| Ecron Acunova A/S |
